The first public presentation of the GED-031 phase II data will be on Oct. 21 at a European medical conference.
The Ebola outbreak in West Africa is a public health emergency which has also captured the attention of U.S. investors (perhaps I should say traders.)
Tetraphase is on track to begin second portion of pivotal study in the fourth quarter.
Tetraphase will report data from a phase III study of eravacycline in which the experimental antibiotic is first given by intravenous infusion and then transitioned to an oral form.
Epizyme's technology platform focuses on developing drugs to regulate a class of cancer-causing enzymes.
Imbruvica will be an important part of the treatment landscape for blood cancers.
If biotech companies can assuage concerns about long-term growth, multiples might expand.
The Seattle Genetics' bull thesis will be tested when results are announced from the "AETHERA" study of Adcetris in post-stem cell transplant Hodgkin's lymphoma patients.
The year is halfway over, so it's a good time to look back and give mid-term grades on my fearless 2014 predictions.
Is a slowdown in Sovaldi prescriptions the beginning of the highly anticipated "re-warehousing" of patients, or is some other factor at play?